posted on 2013-11-14, 00:00authored byAya Yamamura, Qiang Guo, Hisao Yamamura, Adriana M. Zimnicka, Nicole M. Pohl, Kimberly A. Smith, Ruby A. Fernandez, Amy Zeifman, Ayako Makino, Hui Dong, Jason X.-J. Yuan
Rationale: A rise in cytosolic Ca2+ concentration ([Ca2+]cyt) in pulmonary arterial smooth muscle
cells (PASMC) is an important stimulus for pulmonary vasoconstriction and vascular remodeling.
Increased resting [Ca2+]cyt and enhanced Ca2+ influx have been implicated in PASMC from
patients with idiopathic pulmonary arterial hypertension (IPAH).
Objective: We examined whether the extracellular Ca2+-sensing receptor (CaSR) is involved in
the enhanced Ca2+ influx and proliferation in IPAH-PASMC and whether blockade of CaSR
inhibits experimental pulmonary hypertension.
Methods and Results: In normal PASMC superfused with Ca2+-free solution, addition of 2.2
mM Ca2+ to the perfusate had little effect on [Ca2+]cyt. In IPAH-PASMC, however, restoration of
extracellular Ca2+ induced a significant increase in [Ca2+]cyt. Extracellular application of spermine
also markedly raised [Ca2+]cyt in IPAH-PASMC, but not in normal PASMC. The calcimimetic
R568 enhanced, whereas the calcilytic NPS 2143 attenuated, the extracellular Ca2+-induced
[Ca2+]cyt rise in IPAH-PASMC. Furthermore, the protein expression level of CaSR in
IPAH-PASMC was greater than in normal PASMC; knockdown of CaSR in IPAH-PASMC with
siRNA attenuated the extracellular Ca2+-mediated [Ca2+]cyt increase and inhibited IPAH-PASMC
proliferation. Using animal models of pulmonary hypertension, our data showed that CaSR
expression and function were both enhanced in PASMC, whereas intraperitoneal injection of the
calcilytic NPS 2143 prevented the development of pulmonary hypertension and right ventricular
hypertrophy in rats injected with monocrotaline and mice exposed to hypoxia.
Conclusions: The extracellular Ca2+-induced increase in [Ca2+]cyt due to upregulated CaSR is a
novel pathogenic mechanism contributing to the augmented Ca2+ influx and excessive PASMC
proliferation in patients and animals with pulmonary arterial hypertension.
Funding
This work was supported, in part, by grants from the National Heart, Lung, and Blood
Institute of the National Institutes of Health (HL066012 and HL098053 to JX-JY).